Ulcerative Colitis

Ulcerative Colitis - Pipeline Review, H1 2020 https://marketpublishers.com/r/U44188EFA0EEN.html Date: April 2020 Pages: 671 Price: US$ 2,000.00 (Single User License) ID: U44188EFA0EEN

Abstracts

Ulcerative Colitis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players

Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected]

involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre- Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 19, 53, 32, 2, 76 and 14 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 12 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected]

The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected]

Contents

Introduction Ulcerative Colitis - Overview Ulcerative Colitis - Therapeutics Development Ulcerative Colitis - Therapeutics Assessment Ulcerative Colitis - Companies Involved in Therapeutics Development Ulcerative Colitis - Drug Profiles Ulcerative Colitis - Dormant Projects Ulcerative Colitis - Discontinued Products Ulcerative Colitis - Product Development Milestones Appendix

Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected]

List Of Tables

LIST OF TABLES

Number of Products under Development for Ulcerative Colitis, H1 2020 Number of Products under Development by Companies, H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020 Number of Products under Development by Companies, H1 2020 (Contd..7), H1 2020 Number of Products under Development by Universities/Institutes, H1 2020 Products under Development by Companies, H1 2020 Products under Development by Universities/Institutes, H1 2020 Number of Products by Stage and Target, H1 2020 Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020 Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020 Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020 Number of Products by Stage and Route of Administration, H1 2020 Number of Products by Stage and Molecule Type, H1 2020 Ulcerative Colitis - Pipeline by 4D Pharma Plc, H1 2020 Ulcerative Colitis - Pipeline by AbbVie Inc, H1 2020 Ulcerative Colitis - Pipeline by AbGenomics International Inc, H1 2020 Ulcerative Colitis - Pipeline by Abivax SA, H1 2020 Ulcerative Colitis - Pipeline by Aclaris Therapeutics Inc, H1 2020 Ulcerative Colitis - Pipeline by Affilogic SAS, H1 2020 Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, H1 2020 Ulcerative Colitis - Pipeline by Akeso Biopharma Inc, H1 2020

Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected]

List Of Figures

LIST OF FIGURES

Number of Products under Development for Ulcerative Colitis, H1 2020 Number of Products under Development by Companies, H1 2020 Number of Products by Top 10 Targets, H1 2020 Number of Products by Stage and Top 10 Targets, H1 2020 Number of Products by Top 10 Mechanism of Actions, H1 2020 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020 Number of Products by Top 10 Routes of Administration, H1 2020 Number of Products by Stage and Top 10 Routes of Administration, H1 2020 Number of Products by Top 10 Molecule Types, H1 2020 Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4D Pharma Plc AbbVie Inc AbGenomics International Inc Abivax SA Aclaris Therapeutics Inc Affilogic SAS Akebia Therapeutics Inc Akeso Biopharma Inc Algernon Pharmaceuticals Inc Alivio Therapeutics Inc Allergan Plc Alpha Cancer Technologies Inc Alvotech ehf Am-Pharma BV Amgen Inc Antibe Therapeutics Inc Apidel SA Applied Molecular Transport LLC Arena Pharmaceuticals Inc Artelo Biosciences Inc AsiaBiome Asta Pharmaceuticals Co Ltd

Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected]

Atlantic Bio Sci LLC Atlantic Healthcare Plc Avexegen Therapeutics Inc Axim Biotechnologies Inc Bilix Co Ltd BioXpress Therapeutics SA Boehringer Ingelheim International GmbH Bridge Biotherapeutics Inc Bristol-Myers Squibb Co Cellix Bio Pvt Ltd Celltrion Inc Chain Biotechnology Ltd ChemoCentryx Inc Chong Kun Dang Pharmaceutical Corp Circle33 LLC Cloud Pharmaceuticals Inc Cosmo Pharmaceuticals NV Cristcot HCA LLC CrystalGenomics Inc Cureveda LLC Cytocom Inc Dadang & BIO Co Ltd DeNovX LLC Devonian Health Group Inc DM Bio Ltd DNX Biopharmaceuticals Inc Dr. August Wolff GmbH & Co KG Arzneimittel EA Pharma Co Ltd Eli Lilly and Co Enceladus Pharmaceuticals BV enGene Inc Exeliom Biosciences SAS F. Hoffmann-La Roche Ltd Ferring International Center SA Finch Therapeutics Group First Wave Bio Inc FYB202 GmbH & Co KG Galapagos NV Genentech Inc

Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected]

Gilead Sciences Inc GlaxoSmithKline Plc GLW Pharma Gossamer Bio Inc Guangzhou Magpie Pharmaceutical Co Ltd Hefei Cosource Pharmaceutical Inc Holy Stone Healthcare Co Ltd Ichnos Sciences Inc Iltoo Pharma Immunic Inc Impetis Biosciences Ltd Inception Sciences Inc InDex Pharmaceuticals Holding AB Innovate Biopharmaceuticals Inc Innovation Pharmaceuticals Inc Innovent Biologics Inc Innovimmune Biotherapeutics Inc InSight Biopharmaceuticals Ltd Intact Therapeutics Intas Pharmaceuticals Ltd Intract Pharma Ltd Istesso Ltd Jiangsu Hengrui Medicine Co Ltd Johnson & Johnson Kaken Pharmaceutical Co Ltd Kalytera Therapeutics Inc Kintai Therapeutics Inc Koutif Therapeutics LLC Kyowa Kirin Co Ltd Landos Biopharma Inc LG Chem Ltd LIPID THERAPEUTICS GmbH LTT Bio-Pharma Co Ltd MAKScientific LLC Metacrine Inc Microbiotica Ltd Mitsubishi Tanabe Pharma Corp Morphic Holding Inc NeuClone Pty Ltd

Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected]

Nichi-Iko Pharmaceutical Co Ltd Novartis AG Nubiyota LLC Numedii Inc Nyrada Inc Oncodesign SA Oncostellae SL OSE Immunotherapeutics Ovamed GmbH Palatin Technologies Inc Palo BioFarma SL Pandion Therapeutics Inc PanTheryx Inc Paradigm Biopharmaceuticals Ltd Pfizer Inc Pharmapraxis Pharmaxis Ltd PNB Vesper Life Science Pvt Ltd Praeventix LLC Protab Ltd Protagonist Therapeutics Inc Protalix BioTherapeutics Inc Provention Bio Inc Qu Biologics Inc Re-Pharm Ltd Rebiotix Inc Regentys Corp ReveraGen BioPharma Inc RhemaStem SRLS Salix Pharmaceuticals Ltd Saniona AB Sareum Holdings Plc Semorex Technologies Ltd Seres Therapeutics Inc Servatus Ltd Shaperon Inc Siam Bioscience Co Ltd StemRIM Inc sterna biologicals Gmbh & Co KG

Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected]

Sublimity Therapeutics HoldCo Ltd Suzhou Connect Biopharmaceuticals Ltd Swedish Orphan Biovitrum AB Synedgen Inc Synlogic Inc Takeda Pharmaceutical Co Ltd Tarus Therapeutics Inc TheraSource LLC Theravance Biopharma Inc Thetis Pharmaceuticals LLC Tianjin Hemay Pharmaceutical Co Ltd Tillotts Pharma AG TopiVert Ltd Torrent Pharmaceuticals Ltd Ventria Bioscience Vivreon Biosciences LLC Voronoi

Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected]

I would like to order

Product name: Ulcerative Colitis - Pipeline Review, H1 2020 Product link: https://marketpublishers.com/r/U44188EFA0EEN.html Price: US$ 2,000.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [email protected]

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/U44188EFA0EEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature ______

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

Ulcerative Colitis - Pipeline Review, H1 2020